KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Liabilities and Shareholders Equity: 2009-2024

Historic Liabilities and Shareholders Equity for Exact Sciences (EXAS) over the last 16 years, with Dec 2024 value amounting to $5.9 billion.

  • Exact Sciences' Liabilities and Shareholders Equity fell 12.57% to $5.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $23.3 billion, marking a year-over-year decrease of 11.16%. This contributed to the annual value of $5.9 billion for FY2024, which is 8.39% down from last year.
  • Latest data reveals that Exact Sciences reported Liabilities and Shareholders Equity of $5.9 billion as of FY2024, which was down 8.39% from $6.5 billion recorded in FY2023.
  • Exact Sciences' Liabilities and Shareholders Equity's 5-year high stood at $6.7 billion during FY2021, with a 5-year trough of $4.9 billion in FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $6.2 billion (2022), whereas its average is $6.2 billion.
  • Per our database at Business Quant, Exact Sciences' Liabilities and Shareholders Equity skyrocketed by 40.49% in 2020 and then fell by 8.39% in 2024.
  • Exact Sciences' Liabilities and Shareholders Equity (Yearly) stood at $4.9 billion in 2020, then surged by 35.73% to $6.7 billion in 2021, then decreased by 6.85% to $6.2 billion in 2022, then rose by 3.93% to $6.5 billion in 2023, then decreased by 8.39% to $5.9 billion in 2024.